Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Weekly in Cancer Patients with Chemotherapy-Induced Anemia Read more about Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Weekly in Cancer Patients with Chemotherapy-Induced Anemia
Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia Read more about Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia
Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia Read more about Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia
Amgen Announces Expiration and Results of its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032 Read more about Amgen Announces Expiration and Results of its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032
Amgen Announces One-Day Extension of Its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032 Read more about Amgen Announces One-Day Extension of Its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032
Amgen Announces Plans to Webcast Selected Management Presentations Read more about Amgen Announces Plans to Webcast Selected Management Presentations
Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy for First-Line Treatment of Metastatic Colorectal Cancer; Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy Read more about Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy for First-Line Treatment of Metastatic Colorectal Cancer; Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy
Amgen Reports Fourth Quarter and Full Year 2001 Financial Results in Line With Guidance Read more about Amgen Reports Fourth Quarter and Full Year 2001 Financial Results in Line With Guidance
Amgen Announces Webcast of Fourth-Quarter and Full Year 2001 Financial Results Read more about Amgen Announces Webcast of Fourth-Quarter and Full Year 2001 Financial Results
Amgen Announces Award for Science Teaching Excellence; First Year Focusing on Science Teaching Read more about Amgen Announces Award for Science Teaching Excellence; First Year Focusing on Science Teaching
